Provider Alert! COVID-19 Disaster Declaration – COVID-19 Testing expanded to include Out-of- Network (OON) LaboratoriesTexas Children's Health Plan
Attention: All Providers
Effective Date: NEW update for dates of service on or after March 20, 2020
Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
The content in this message will remain in effect throughout the COVID-19 Disaster Declaration period as announced by the office of the Texas Governor, Greg Abbott.
COVID-19 Utilization Management Procedure and provider alerts can be found here: http://www.thecheckup.org/provider-alerts/
Call to action:
Quest Diagnostics (Quest) is TCHP’s exclusive lab provider. Quest is continuously working to expand their capacity for COVID-19 testing and ensure timely turnaround of results. As a result of the COVID-19 disaster declaration, TCHP has instituted the following through the disaster declaration period.. At that time, TCHP will reassess the need for an extension.
In order to increase access to COVID-19 testing services TCHP will temporarily accept claims from Out of Network (OON) Laboratory providers for COVID19 diagnostic testing only. TCHP will consider claims under the following circumstances only:
Update effective for dates of service on or after March 20, 2020:
- Procedure code U0002 must be submitted with modifier QW. The provider must bill using the appropriate COVID-19 procedural coding.
- The Centers for Medicare & Medicaid services (CMS) has issued two new procedure codes for COVID-19 testing.
- U0002 (A laboratory test that is not the CDC-developed test kit-any technique)
- U0001 (for CDC-developed test kit). The codes are effective April 1, 2020 for dates of service on or after February 4, 2020.
- New CPT code for use on or after March 13, 2020, 87635 (a laboratory test that is not the CDC-developed test kit- amplified probe technique).
Reference: Update to “Coronavirus Testing Procedure Codes to Become a Benefit”
- CMS has issued two new HCPCS codes for lab tests that use high-throughput technologies to test for COVID-19. Providers can submit these codes for dates of service on or after April 14, 2020:
- U0003 – A laboratory test performed using high-throughput technologies that is not the CDC-developed test kit (amplified probe technique)
- U0004 – A laboratory test performed using high-throughput technologies that is not the CDC-developed test kit (any technique)
- The American Medical Association (AMA) announced one revised CPT code and two new CPT codes that providers can submit for antibody testing for dates of service on or after April 10, 2020:
- 86318 – Multiple infectious agents antibody testing performed using a single-step method immunoassay (Revised)
- 86328 – COVID-19 Antibody testing performed using a single step method immunoassay
- 86769 – COVID-19 Antibody testing performed using a multiple step method
- CMS has issued two new HCPCS codes for COVID-19 specimen collection. Laboratories can submit these codes for dates of service on or after March 1, 2020:
- G2023 – Specimen collection, any specimen source (for use by laboratories only)
- G2024 – Specimen collection from an individual in a skilled nursing facility or by a laboratory on behalf of a home health agency, any specimen source (for use by laboratories only)
- All other providers may continue to bill for the COVID-19 specimen collection using one of these existing codes:
- 99001 – Handling and/or conveyance of specimen
- 99211 – Established office visit not requiring the presence of a physician
- The provider must have a valid NPI number that has been attested to with Texas Medicaid;
- The provider must be a CLIA certified laboratory for high complexity lab testing.
- The provider must include their CLIA certificate number on the submitted claim for the billing laboratory;
- For Electronic Claims Submission for the billing laboratory include the CLIA certificate number in X12N 837 (HIPAA version) loop 2300, for REF02 and X4 ƒ ANSI for REF01.
For the laboratory, include in X12N 837 (HIPAA version) loop 2400 for REF02 and F4 for REF01.
- For Paper claims – include the CLIA certificate number in item 23 on the CMS-1500 billing form.
The provider must be FDA certified for COVID-19 testing.
NOTE: Claims must be submitted based on all established Texas Medicaid and national claim coding standards.
How this impacts providers:
- Clean claims accepted for adjudication will be reimbursed at 100% of the Texas Medicaid allowable rate established for COVID-19 testing. Please note that acceptance of a claim is not a guarantee of payment. The claim will be adjudicated at the time of submission, at which time the service will be evaluated based on the member’s eligibility and benefits status for the submitted date of service. All applicable rules and standards set forth for Texas Medicaid and TCHP claim adjudication will apply.
- Provider claims are subject to information validation upon post-payment review and are subject to recovery efforts should the above-defined criteria for claim submission not be verifiable.
Testing for medically fragile members receiving care at home:
TCHP aligns with HHSC guidance regarding specimen collection in the home as long as a trained professional is performing the collection and proper storage instructions are followed it is permitted.
Providers with a Certificate of Waiver are allowed to perform and bill procedure codes 87635 and U0002 with the QW modifier.
If you have any questions, please email Provider Network Management at: email@example.com.